Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Michael J. Joyner, Rickey E. Carter, Jonathon W. Senefeld, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 11, pp. 1015-1027
Open Access | Times Cited: 513

Showing 1-25 of 513 citing articles:

Mechanisms of SARS-CoV-2 entry into cells
Cody B. Jackson, Michael Farzan, Bing Chen, et al.
Nature Reviews Molecular Cell Biology (2021) Vol. 23, Iss. 1, pp. 3-20
Open Access | Times Cited: 2410
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2021) Vol. 397, Iss. 10289, pp. 2049-2059
Open Access | Times Cited: 471
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Vanessa Piechotta, Khai Li Chai, Sarah J Valk, et al.
Cochrane library (2020)
Open Access | Times Cited: 327
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer, Jennifer A. Juno, David S. Khoury, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 395-404
Open Access | Times Cited: 258
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
Philippe Bégin, Jeannie Callum, Erin Jamula, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2012-2024
Open Access | Times Cited: 243
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Vanessa Piechotta, Claire Iannizzi, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 5
Open Access | Times Cited: 188
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Michael A. Thompson, Jeffrey P. Henderson, Pankil Shah, et al.
JAMA Oncology (2021) Vol. 7, Iss. 8, pp. 1167-1167
Open Access | Times Cited: 171
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
Max R. O’Donnell, Beatriz Grinsztejn, Matthew J. Cummings, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 13
Open Access | Times Cited: 160
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Arvind Gharbharan, Carlijn Jordans, Corine H. GeurtsvanKessel, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 148
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
Stephen A. Klassen, Jonathon W. Senefeld, Patrick W. Johnson, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 5, pp. 1262-1275
Open Access | Times Cited: 148
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants
Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
PLoS Medicine (2021) Vol. 18, Iss. 7, pp. e1003656-e1003656
Open Access | Times Cited: 140
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
Frederick K. Korley, Valerie Durkalski‐Mauldin, Sharon D. Yeatts, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 21, pp. 1951-1960
Open Access | Times Cited: 140
Antibody Responses in COVID-19: A Review
Mateo Chvatal-Medina, Yorjagis Mendez-Cortina, Pablo Javier Patiño Grajales, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 137
Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study
Javier García-Abellán, Sergio Padilla, Marta Fernández‐González, et al.
Journal of Clinical Immunology (2021) Vol. 41, Iss. 7, pp. 1490-1501
Open Access | Times Cited: 136
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
Lamiaa El-Shennawy, Andrew D. Hoffmann, Nurmaa K. Dashzeveg, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 136
SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
Ilias Bensouna, Valérie Caudwell, Sabah Kubab, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 2, pp. 185-192.e1
Open Access | Times Cited: 126
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay
Katarina Resman Rus, Miša Korva, Nataša Knap, et al.
Journal of Clinical Virology (2021) Vol. 139, pp. 104820-104820
Open Access | Times Cited: 108
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
C. Avendaño, António Ramos, Elena Múñez, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 20
Open Access | Times Cited: 104
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yuanling Yu, Meiyu Wang, Xiao‐Ai Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 101
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 89
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients
Benoît Misset, Michaël Piagnerelli, Eric A. J. Hoste, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 17, pp. 1590-1600
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top